However, pharmacological targeting of ACKR3/CXCR7 by administration of CXCR7-agonist TC14012 retards cardiac hypertrophy in these mice, suggesting its therapeutic efficacy in counteracting adverse remodeling. The gene discussed is ACKR3; the disease is cardiac hypertrophy.